Scientists hunt for clues to improve leukemia treatment after transplant
NCT ID NCT07627568
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at blood cells from 20 adults with acute myeloid leukemia (AML) whose cancer returned after a stem cell transplant. All participants have specific genetic changes (NPM1 mutations or KMT2A rearrangements) and are being treated with a menin inhibitor. Researchers will measure certain biomarkers to see if they relate to how well the leukemia responds or how long patients survive. The goal is to learn more, not to test a new treatment directly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
menin inhibitor
What this could lead to
If successful, this could help identify which patients might respond to menin inhibitors after a stem cell transplant, potentially guiding future treatment decisions.
What could go wrong
This is a very small, early biomarker study with only 20 participants. It is not designed to test whether the treatment works, only to look for biological signals.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Freiburg Mdical Center
RECRUITINGFreiburg im Breisgau, 79106, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••